Results 241 to 250 of about 238,222 (362)
Response to “Sequential Portal Vein–Hepatic Vein Embolization: Progress Yet Unaccounted Pitfalls”
Annals of Gastroenterological Surgery, EarlyView.
Thanh Tung Lai, Masaki Kaibori
wiley +1 more source
American Journal of Hematology, EarlyView.A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova +10 more
wiley +1 more source
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Biallelic pathogenic variants in AKR1D1 cause Δ4‐3‐oxosteroid 5β‐reductase deficiency, disrupt bile acid synthesis, and result in Congenital Bile Acid Synthesis defect type 2 (CBAS2). CBAS2 presents in infancy with cholestasis, coagulopathy, and failure to thrive.
Jade Hudson +3 more
wiley +1 more source
Chronic Liver Disease, Not Everything Is What It Seems: Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome [PDF]
Bruna Rodrigues Barbosa +3 more
openalex +1 more source
Characterization of inflammatory pseudotumors in a large animal model of liver cancer
Animal Models and Experimental Medicine, EarlyView.CT images in arterial and portal venous phases of liver lesions in Oncopig. Abstract Background The development of relevant and robust large animal models of hepatocellular carcinoma is needed to test new therapeutic strategies for this disease. Transgenic approaches hold promise in addressing this complex problem. One such model, the Oncopig, has been
Erik N. K. Cressman +4 more
wiley +1 more source
Pathological patterns of biliary disease. [PDF]
Clin Liver Dis (Hoboken), 2017 Lewis J.
europepmc +1 more source